AstraZeneca

AstraZeneca’s IMFINZI® Granted Priority Review for Early-Stage Gastric Cancer Treatment

WILMINGTON, DE — The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) in the treatment of …

AstraZeneca’s IMFINZI® Granted Priority Review for Early-Stage Gastric Cancer Treatment Read More